Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.18 CHF | +1.67% | +0.37% | +18.92% |
06-07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
05-22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.92% | 15.25B | |
+19.64% | 42.33B | |
+21.25% | 22.47B | |
+53.19% | 12.6B | |
-0.05% | 6.79B | |
-11.11% | 6.71B | |
-8.87% | 5.73B | |
+14.68% | 5.47B | |
+6.91% | 4.78B | |
+23.64% | 4.46B |
- Stock Market
- Equities
- SDZ Stock
- News Sandoz Group AG
- Transcript : Sandoz Group AG, Q4 2023 Earnings Call, Mar 13, 2024